FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799931007> ?p ?o ?g. }

• W2799931007 endingPage "833" @default.
• W2799931007 startingPage "825" @default.
• W2799931007 abstract "Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments.In this single-arm, single-centre, phase 2 trial, we recruited men (aged 18 years and older) with metastatic castration-resistant prostate cancer and progressive disease after standard treatments, including taxane-based chemotherapy and second-generation anti-androgens, from the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Patients underwent a screening PSMA and FDG-PET/CT to confirm high PSMA-expression. Eligible patients had progressive disease defined by imaging (according to Response Evaluation Criteria In Solid Tumours [RECIST] or bone scan) or new pain in an area of radiographically evident disease, and were required to have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or lower. Eligible patients received up to four cycles of intravenous [177Lu]-PSMA-617, at six weekly intervals. The primary endpoint was PSA response according to Prostate Cancer Clinical Trial Working Group criteria defined as a greater than 50% PSA decline from baseline and toxicity according to CTCAE. Additional primary endpoints were imaging responses (as measured by bone scan, CT, PSMA, and FDG PET/CT) and quality of life (assessed with the EORTC-Q30 and Brief Pain Inventory-Short Form questionnaires), all measured up to 3 months post completion of treatment. This trial is registered with the Australian New Zealand Clinical Trials Registry, number 12615000912583.Between Aug 26, 2015, and Dec 8, 2016, 43 men were screened to identify 30 patients eligible for treatment. 26 (87%) had received at least one line of previous chemotherapy (80% docetaxel and 47% cabazitaxel) and 25 (83%) received prior abiraterone acetate, enzalutamide, or both. The mean administered radioactivity was 7·5 GBq per cycle. 17 (57%) of 30 patients (95% CI 37-75) achieved a PSA decline of 50% or more. There were no treatment-related deaths. The most common toxic effects related to [177Lu]-PSMA-617 were grade 1 dry mouth recorded in 26 (87%) patients, grade 1 and 2 transient nausea in 15 (50%), and G1-2 fatigue in 15 (50%). Grade 3 or 4 thrombocytopenia possibly attributed to [177Lu]-PSMA-617 occurred in four (13%) patients. Objective response in nodal or visceral disease was reported in 14 (82%) of 17 patients with measurable disease. Clinically meaningful improvements in pain severity and interference scores were recorded at all timepoints. 11 (37%) patients experienced a ten point or more improvement in global health score by the second cycle of treatment.Our findings show that radionuclide treatment with [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments. This evidence supports the need for randomised controlled trials to further assess efficacy compared with current standards of care.None." @default.
• W2799931007 created "2018-05-17" @default.
• W2799931007 creator A5002564826 @default.
• W2799931007 creator A5020420969 @default.
• W2799931007 creator A5020993128 @default.
• W2799931007 creator A5028575111 @default.
• W2799931007 creator A5029076956 @default.
• W2799931007 creator A5036019382 @default.
• W2799931007 creator A5039260287 @default.
• W2799931007 creator A5044519122 @default.
• W2799931007 creator A5045912081 @default.
• W2799931007 creator A5047242510 @default.
• W2799931007 creator A5063276705 @default.
• W2799931007 creator A5064026461 @default.
• W2799931007 creator A5066214064 @default.
• W2799931007 creator A5070501683 @default.
• W2799931007 creator A5082622296 @default.
• W2799931007 date "2018-06-01" @default.
• W2799931007 modified "2023-10-17" @default.
• W2799931007 title "[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study" @default.
• W2799931007 cites W1546799663 @default.
• W2799931007 cites W1935621952 @default.
• W2799931007 cites W2009041257 @default.
• W2799931007 cites W2027847537 @default.
• W2799931007 cites W2055346449 @default.
• W2799931007 cites W2076668534 @default.
• W2799931007 cites W2080677976 @default.
• W2799931007 cites W2093274439 @default.
• W2799931007 cites W2103607521 @default.
• W2799931007 cites W2105337740 @default.
• W2799931007 cites W2123526148 @default.
• W2799931007 cites W2141454098 @default.
• W2799931007 cites W2147136637 @default.
• W2799931007 cites W2148643283 @default.
• W2799931007 cites W2155263737 @default.
• W2799931007 cites W2167331614 @default.
• W2799931007 cites W2167571044 @default.
• W2799931007 cites W2303817381 @default.
• W2799931007 cites W2304896218 @default.
• W2799931007 cites W2397136240 @default.
• W2799931007 cites W2518199070 @default.
• W2799931007 cites W2523333323 @default.
• W2799931007 cites W2525124727 @default.
• W2799931007 cites W2532226140 @default.
• W2799931007 cites W2573369749 @default.
• W2799931007 cites W2606187374 @default.
• W2799931007 cites W2664930764 @default.
• W2799931007 cites W2917837889 @default.
• W2799931007 doi "https://doi.org/10.1016/s1470-2045(18)30198-0" @default.
• W2799931007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29752180" @default.
• W2799931007 hasPublicationYear "2018" @default.
• W2799931007 type Work @default.
• W2799931007 sameAs 2799931007 @default.
• W2799931007 citedByCount "762" @default.
• W2799931007 countsByYear W27999310072018 @default.
• W2799931007 countsByYear W27999310072019 @default.
• W2799931007 countsByYear W27999310072020 @default.
• W2799931007 countsByYear W27999310072021 @default.
• W2799931007 countsByYear W27999310072022 @default.
• W2799931007 countsByYear W27999310072023 @default.
• W2799931007 crossrefType "journal-article" @default.
• W2799931007 hasAuthorship W2799931007A5002564826 @default.
• W2799931007 hasAuthorship W2799931007A5020420969 @default.
• W2799931007 hasAuthorship W2799931007A5020993128 @default.
• W2799931007 hasAuthorship W2799931007A5028575111 @default.
• W2799931007 hasAuthorship W2799931007A5029076956 @default.
• W2799931007 hasAuthorship W2799931007A5036019382 @default.
• W2799931007 hasAuthorship W2799931007A5039260287 @default.
• W2799931007 hasAuthorship W2799931007A5044519122 @default.
• W2799931007 hasAuthorship W2799931007A5045912081 @default.
• W2799931007 hasAuthorship W2799931007A5047242510 @default.
• W2799931007 hasAuthorship W2799931007A5063276705 @default.
• W2799931007 hasAuthorship W2799931007A5064026461 @default.
• W2799931007 hasAuthorship W2799931007A5066214064 @default.
• W2799931007 hasAuthorship W2799931007A5070501683 @default.
• W2799931007 hasAuthorship W2799931007A5082622296 @default.
• W2799931007 hasConcept C121608353 @default.
• W2799931007 hasConcept C126322002 @default.
• W2799931007 hasConcept C126894567 @default.
• W2799931007 hasConcept C143998085 @default.
• W2799931007 hasConcept C203092338 @default.
• W2799931007 hasConcept C2776235491 @default.
• W2799931007 hasConcept C2776694085 @default.
• W2799931007 hasConcept C2777511904 @default.
• W2799931007 hasConcept C2778822529 @default.
• W2799931007 hasConcept C2779984678 @default.
• W2799931007 hasConcept C2780192828 @default.
• W2799931007 hasConcept C530470458 @default.
• W2799931007 hasConcept C535046627 @default.
• W2799931007 hasConcept C71924100 @default.
• W2799931007 hasConceptScore W2799931007C121608353 @default.
• W2799931007 hasConceptScore W2799931007C126322002 @default.
• W2799931007 hasConceptScore W2799931007C126894567 @default.
• W2799931007 hasConceptScore W2799931007C143998085 @default.
• W2799931007 hasConceptScore W2799931007C203092338 @default.
• W2799931007 hasConceptScore W2799931007C2776235491 @default.
• W2799931007 hasConceptScore W2799931007C2776694085 @default.
• W2799931007 hasConceptScore W2799931007C2777511904 @default.

• next